INVA Assumes Outperform by Oppenheimer -- Price Target Announced at $35

gurufocus.com · 2026-09-23

Innoviva (INVA) Analyst Rating Update On October 3, 2023, Oppenheimer has assumed an Outperform rating for Innoviva (INVA), with an announced price target of

TickrTrends take: Oppenheimer's outperform rating and $35 price target for INVA provides a reference point for assessing whether the stock's current market price aligns with analyst expectations in the Healthcare sector. Given that TickrTrends currently rates INVA as fairly valued, investors should monitor whether the market reprices the stock toward Oppenheimer's target or whether fundamental factors emerge that validate or challenge this valuation perspective. The analyst's positive outlook suggests confidence in INVA's business trajectory, making it relevant to watch how the company's execution tracks against the expectations embedded in both the current valuation and the stated price target.

Read the full story at gurufocus.com →